Evaluation of the impacts of autologous hematopoietic stem cell transplantation on patients with multiple myeloma
DOI:
https://doi.org/10.33448/rsd-v11i16.38328Keywords:
Neoplasm; Treatment; Diagnosis; Prognosis.Abstract
Introduction: Multiple myeloma is a neoplasm characterized by uncontrolled proliferation of plasma cells. In the current scenario, several therapeutic protocols are used in the treatment of MM, so that the different disorders caused by neoplastic cells define which is the best treatment to be used, being the gold standard the autologous hematopoietic stem cell transplantation. Objective: To evaluate the influence of autologous HSCT on the prognosis of patients with multiple myeloma compared to other therapeutic options, taking into consideration clinical and laboratory factors, and to discuss the advantages and disadvantages of autologous hematopoietic stem cell transplantation. Methodology: This is a qualitative descriptive literature review based on bibliographies available at SciELO, PubMed and LILACS. Results: With the scientific advances promoted by research focused on the treatment of patients with MM, there has been an increase in the survival of patients diagnosed with the disease in recent years. One of the advances that contributed to this improvement was the use of autologous hematopoietic stem cell transplantation (HSCT) as part of the treatment for the disease. Conclusion: Autologous hematopoietic stem cell transplantation, associated with other techniques involved in the treatment of multiple myeloma, is shown to be favorable for patient recovery due to the capacity of replacement and renewal of normal cells promoted by transplanted cells.
References
Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., ... & Moreau, P. (2017). Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. New England Journal of Medicine, 376(14), 1311-1320.
Bardin, L. (2011). Analise de Conteúdo. São Paulo: Ed. Revista e Ampliada.
Buon, E., Guang, M. H. Z., & Bianchi, G. (2018). Leukaemia Section. http://AtlasGeneticsOncology. org, 497.
Dambros, V. L., Gasparetto, C., Costella, G., Azevedo, V., Trevizan, S., Heck, L. H., ... & Costa, M. G. (2021). análise dos transplantes de medula óssea realizados no brasil entre 2015 E 2020. Hematology, Transfusion and Cell Therapy, 43, S247-S248.
GIL, C., & de Pesquisa, A. C. E. P. (2017). 6ª edição. São Paulo, Atlas.
IMF. (2020). Estadiamento do Mieloma. Atualizado em 2020. International Myeloma Foundation (IMF). https://myeloma.org.br/quais-testes-voce-precisa/.
Massumoto, C., & Mizukami, S. (2000). Transplante autólogo de medula óssea e imunoterapia pós-transplante. Medicina (Ribeirão Preto), 33(4), 405-414.
Mian, H., Mian, O. S., Rochwerg, B., Foley, R., & Wildes, T. M. (2020). Autologous stem cell transplant in older patients (age≥ 65) with newly diagnosed multiple myeloma: A systematic review and meta-analysis. Journal of Geriatric Oncology, 11(1), 93-99.
Mikhael, J., Ismaila, N., Cheung, M. C., Costello, C., Dhodapkar, M. V., Kumar, S., ... & Martin, T. (2019). Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. Journal of Clinical Oncology, 37(14), 1228-1263.
MSAG. (2017). Multiple myeloma. Clinical Practice Guideline, v. 4. Medical Scientific Advisory Group.
Ntanasis-Stathopoulos, I., Gavriatopoulou, M., Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2020). Multiple myeloma: Role of autologous transplantation. Cancer treatment reviews, 82, 101929.
Pinheiro, E. N., Santos, R. M. P. D., Silva, A. L., Silva, A. J. M. E., Reis, G. S. C., Castro, L. M. S., ... & Berg, A. V. S. V. D. (2021). Intercorrência pós transplante de células-tronco hematopoiéticas: comparação entre os casos de transplante autólogo e alogênico nos últimos 10 anos. Hematology, Transfusion and Cell Therapy, 43, S197.
Rajkumar, S. V. (2018). Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management. American journal of hematology, 93(8), 1091-1110.
Reis, M. A., & Visentainer, J. E. (2004). Reconstituição imunológica após o transplante de medula óssea alogênico. Revista Brasileira de Hematologia e Hemoterapia, 26, 212-217.
Salema, C. L. Z., & de Carvalho, C. (2019). Diagnósticos, tratamentos e prognósticos do mieloma múltiplo. Revista Ciência e Saúde On-line, 4(1).
Schein, C. F., Marques, A. R., Vargas, C. L., & Kirsten, V. R. (2006). Efeitos colaterais da quimioterapia em pacientes oncológicos hospitalizados. Disciplinarum Scientia| Saúde, 7(1), 101-107.
Silva, C. F. M., Mendonça, C. V., Cuquetto, G. M., Campos, A. S. C. P., Barros, T. A., & Schaffel, R. (2022). Transplante autólogo de medula óssea com produto criopreservado versus não criopreservado em pacientes portadores de mieloma múltiplo. Hematology, Transfusion and Cell Therapy, 44, S325.
Silva, M. J. S., & de Souza, P. G. V. D. (2020). Desenvolvimento de doenças e complicações após transplante de medula óssea. Brazilian Journal of Development, 6(12), 98279-98294.
Vasconcelos, S. D. F. D. N. (2021). Farmacogenómica do Mieloma Múltiplo (Doctoral dissertation).
Wallington-Beddoe, Craig T.; Mynott, Rachel L. Prognostic and predictive biomarker developments in multiple myeloma. Journal of Hematology & Oncology, v. 14, n. 1, p. 1-15, 2021.
Williams, A., Baruah, D., Patel, J., Szabo, A., Chhabra, S., Dhakal, B., ... & D’Souza, A. (2021). Prevalence and significance of sarcopenia in multiple myeloma patients undergoing autologous hematopoietic cell transplantation. Bone marrow transplantation, 56(1), 225-231.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Rafael Santos Andrade Chalega; Lauceny Araújo de Jesus Santos; Ingrid Medeiros de Oliveira; Vinicius Mendes Souza Carneiro
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
